Summary: Cisplatin, a nephrotoxic chemotherapeutic agent, was injected into Sprague Dawley rats, alone or together with cysteine, vitamin E and clonidine. The effects on erythrocyte fragility, serum composition, and kidney and liver enzymes were studied.
Introduction
istration of this drug however results in a significarit . _ _ . · · · · impairment of renal function (6) (7) (8) (9) (10) . czs-Diammme dichloroplatmiim (cisplatin) is an important chemotherapeutic agent used effectively in the treat-Foilowing the administration of cisplatin to rats, both ment of cancers of the testes, ovary, head and neck, the inulin clearance rate and the glomerular filtration bladder, prostate and other organs <l-5). The admin-rate afe reduced (6-l6). Bogin et al.: Changcs in serum, liver and kidneys of cisplatin-treated. rats Tab. l Enzyme catalytic concentrations in sera of conlrol and cisplatin-treated rats Biochemical studies with heavy metals show that they react with free sulphydryl groups. It is postulated that the nephrotoxicity caused by several heavy metals, e. g. mercury, is related to the intracellular decrease of reduced glutathione; enzymes are then inactivated because their SH-groups are not maintained in a reduced form (12) . Levi et al. (15) showed that following the administration of cisplatin to rats, there was a significant decrease of SH groups per gram wet weight. This change was seen prior to the elevation of blood urea nitrogen and creatinine in the blood, suggesting that SH group depletion may be a primary event leading to the renal failure. The decrease of SH groups was due to a decrease of protein-bound SH, with the greatest decline in the cytosolic and mitochrondrial fractions (15) . Ways of protecting SH groups and reducing the toxic effects caused by cisplatin have been repprted (17) (18) (19) .
The objectives of this study were to obtain Information on the effects of cisplatin on various enzyme Systems in the kidney, liver and blood, to relate these effects to renal failure, and to evajuate possible methods of reversing these effects by a administering compounds that protect or increase SH groups.
Materials and Methods
White male, 60 days old Sprague-Dawley rats, weighing 260 ± 10 grams were used. Cisplatin was injected i. p. (6 mg/kg body weight) twice, the second injection, being given 120 hours after the first. The animals were sacrificed 24 hours after the second injection. Blood was taken from the abdominal aorta for the prepration of serum. Haematocrit and erythrocytes mean osmotic fragility were determined on heparinized blood.
Immediately after compiete bleeding and death of the animal, tissues were taken, cooled to 0-4 °C and hornogenized; a cell-free supernatant was prepared for the determination of enzyme levels. Homogenization and fractionation were done according ' to a method previously described by Bogin et al. (20) . Three fractions were obtained: mitochondria, rnicrosomes and soluble fraction.
Liver and kidney tissues were homogenized in 10-fold volumes of sucrose (0.25 mol/1, tris buffer 0.02 mol/1, pH 7.4) with a teflonglass homogenizer. Prior to homogenization, the tissues were cut into small pieces and washed three times with fche homogenizing solution. (34) . Free sulphydryl groups were measured in the supematant according to Sedlak&Lindsäy (35) . Protein in the various fractions was determined according to Lowry et ail. (36) , and the activities were expressed per g protein.
The following constituents were measured in the serum: blood urca nitrogen -enzymaticaUy (37); creatinine -colorimetrically (38); älbumin -colorimetrically (39); total protein -colorimetrically (40); glu'cose -enzyrnatically (41); total lipids -colorimetrically (42); caicium (43) and magnesium (44) -colorimetrically; and inorganic phosphorus -colorimetrically (45) . Mean osmolic fragility of the erythrocytes was measured on freshly withdrawn cells according to Parpart (46) .
Internal (high and low levels) and external (DADE) quality control programs were used.
Trials to reduce the nephrotic effects of cisplatin were performed. The substances evaluated were:
1) cysteinc -a SH-containing amino acid with the potential to protect endogenous SH-groups, and, therefore to reduce the damage causcd by cisplatin;
2) vitamin E, a substance known for its antioxidative activity and thus a potential agent for protection of SH-groups. Cysteine and vitamin E were used together to determine whether the combination of the two offers greater protection;
3) clonidine, a substance used äs a detoxirying agent in cases of heavy metal poisoning (15) . The effects of clonidine and cysteine + vitamin E were studied in the absence and in the presence of cisplatin. Clonidine was given in the drinking water (4.5 mg/1 waler). Cysteine (20 mg/kg body weight) was injected together with cisplatin. Vitamin E (2 mg/rat) was dissolved in corn oil l : 50, and injected s. c. together with cisplatin and cysteine.
Student's t-test was used for statistical analysis of the result.
Results
There were small but significant changes in most serum enzymes studied. While isocitric dehydrogenase and glutathione reductase activities were significantly (p < 0.01) higher in cisplatin-treated rats, the levels of aspartate aminotransferase, alanine aminotransferase, lactic dehydrogenase and alkaline phosphatase were significantly lower. No significant differences were seen in the level of malic dehydrogenase and malic enzyme (tab. l and fig. 1 ).
The concentrations of serum proteins and metabolites in control and cisplatin-treated rats are given in table 2. There were large significant increases in blood urea nitrogen (406%) and creatinine (740%) indicating renal function insufficiency.
Small but significantly (p < 0.01) lower concentrations of blood glucose and serum älbumin and higher total lipids were seen in the sera of cisplatin-treated rats. x ± sem; n = 9 * significantly different (p < 0.01) While serum magnesium was significantly (p < 0.01) higher (4-45%) in the cisplatin-treated rats, serum calcium and inorganic phosphorus did not change (tab. 3) .
The effects of cisplatin on the erythrocytes are shown in table 4. There was a significant (p < 0.01) increase (10%) in the haematocrit and a decrease (5%) in the mean osmotic fragility.
Analysis of the soluble enzyme fraction from liver showed a significant mean increase of 38% (p < 0.01) in the activity of NADP-isocitric dehydrogenase from the cisplatin-treated rats, compared with the controls. There were no significant changes in the other enzymes studied (tab. 5). Levels of soluble enzymes in the kidneys of control and cisplatin-treated rats are shown in table 6 and figure 2. A mixed pattern was seen. Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, malic dehydrogenase, sorbitol dehydrogenase and γ-glutamyltransferase showed significantly (p < 0.01). lower specific actiyities, while glucose 6-phosphate dehydrogenase was significantly higher in the cisplatin-treated rats. No significant changes were seen in the activities of isocitric dehydrogenase, lactic dehydrogenase, malic enzyme and glutathione reduct se.
Measurement of mitochondrial oxidation and phosphorylation showed that the P/O ratio was decreased in mitochondria from the kidneys of cisplatin-treated rats, i. e. these mitochondria were less efficient in the production of adenosine triphosphate. While oxidation levels were almost identical in both groups, phosphorylation was significantly (p < 0.01) lower in the cisplatin-treated group, decreasing the P/O ratio by 15% (tab. 7).
The effects of clonidine, cysteine and vitamin E on changes induced by cisplatin in serum enzymes are given in table 8. While serum aspartate aminotransferase was significantly lower after administration of cisplatin alone, the activity was not significantly different from the control when cisplatin was administered together with clonidine or together with cysteine and vitamin E. Addition of clonidine alone did not significantly change serum aspartate aminotransferase activity. Administration of cysteine and vitamin E alone significantly increased serum aspartate aminotransferase activity by about 22%. This Stimulation however was abolished whenever cisplatin was injected together with cysteine and vitamin E. Cisplatin significantly lowered the activity of alanine aminotransferase, whereas clonidine, or cysteine together with vitamin E, given without cisplatin did not affect serum enzyme activity. Clonidine together with cisplatin did not reverse the lowered activity of the enzyme. Cysteine and vitamin E given together with cisplatin led to an even greater decrease than that seen with cisplatin alone. Cisplatin caused a reduction in the activity of serum lactic dehydrogenase. While clonidine caused a significantly higher activity, cisplatin administered together with clonidine caused an even greater decrease of serum lactic dehydrogenase (tab. 8). Cysteine + vitamin E administered alone, or cisplatin together with cysteine + vitamine E caused no effect on serum malic dehydrogenase activity. Clonidine on the other band led to increased activity of malic dehydrogenase. Cisplatin administered together with cysteine and vitamin E caused a significant decrease of serum malic dehydrogenase.
Cisplatin, clonidine and cysteine + vitamin E, alone or in combination, led to lower serum alkaline phosphatase activity. Clonidine, cysteine and vitamin E did not reverse the inhibitory effect on alkaline phosphatase by cisplatin (tab. 8).
Cisplatin and clonidine led to increased activity of glutathione reductase when added together, and the Stimulation was additive. Cysteine and vitamin E, added alone or together with cisplatin, caused little or no effect on the serum activity of glutathione reductase (tab. 8).
The effects of cisplatin, clonidine, cysteine and vitamin E on kidney enzymes are shown in table 9. Alanine aminotransferase from kidney was lower following cisplatin treatment, while higher activity was seen following treatment with clonidine. Whenever both cisplatin and clonidine were administered together, the effects of each drug were neutralized by the other, so that the activity was similar to that of the untreated control group. Kidney sorbitol dehydrogenase activity was lowered by clonidine and cisplatin, and a cumulative Inhibition was seen whenever both drugs were administered together. Cysteine and vitamin E caused a similar Inhibition to that of cisplatin, but no additive effect was seen (about A nd vitamin E, added alone or together with cisplatin, were seen (tab. 9). While kidney Mg 2+ -adenosine triphosphatase was significantly lower following cisplatin treatment and higher following clonidine treatment, no significant effect was seen in the activity of Na + ,K H~-adenosine triphosphatase. TPjie Inhibition of kidney Mg 2 " h -adenosine triphosphatase was reversed by the addition of clonidine (tab. 9).
The effects of cisplatin, clonidine, cysteine and vitamin E on serum proteins, metabolites and electrolytes are giveii in table 10. Blood urea nitrogen and creatinine increased from rriean values of 8.2 ± 0.3 inmol/1 and 75 ± 6 μιηοΐ/ΐ respectively, to 69 ± 5 mmol/I and 380 ±35 μπιοΐ/ΐ respectively. While clonidine alone had little to no effect on the levels of these metabolites, it significantly increased renal failure when administered together with cisplatin. On the other hand, cysteine and vitamin E significantly reverse some of the effects pf renal failure caused by cisplatin (tab. 10). Administration of cisplatin led to an increase in the serum concentration of Mg pf almpst 50% (p < 0.01). This effect was partially reversed by cysteine and vitamin E but not by clonidine (tab. 10).
Discussion
The present investigatipn focused on the biochemical s-J 1 pects, kinetics and mode of action of toxic effects caused by cisplatin.
The serum enzymes, aspartate aminotransferase, alanine aminotransferase, lactic "defrydrogenase and alkaline phosphatase, s well s others, are commonly elevated following cellular damage s a result of enzymes leakage from cells to the blood. The serum catalytic coneentrations of these enzymes however were significantly lower 120 hours post cisplatin administration in the treated anim ls, suggesting an inhibitory effect. Lower enzyme levels may be due tp either lower release from the tissues to the serum, or decreased production of active enzymes and consequently lower activity in the serum.
It has been postulated that the nephrotoxic mode of aetion of the drug cisplatin is similar to that of other heavy metals, and is related to the decrease in the intracellular concentrations of glutathione and protein-bpund SHgroups, which are required for normal celMar function ··?· (1^5, [8] [9] [10] [11] 14, 15) .
The possibility that cisplatin itself is the inhibitory agent l of the enzymatic reaction was excluded by the fact thatΊ»ι in vitro addition of the drug to the reactioii media did ! not affect the reaction rates .(unpublished bservations). The lower activities of enzymes in the serum parallelled the intracellular pattern. Administration of substances containing sulphydryl groups, or with antioxidant properties, together with cisplatin, significantly reversed the inhibitory effects caused by cisplatin alone, supporting the hypothesis that the cisplatin toxicity is associated with the reduction of free sulphydryl groups.
Addition of both cysteine and vitamin E significantly reversed the toxic effects caused by cisplatin. The degree of uraemia was lowered and the magnitude of the changes in the serum analytes, including glutathione reductase, were smaller. These findings may suggest that some of the toxic effects caused by cisplatin may be reduced by u$ing cysteine and vitamin E. This, however, needs to be further studied, in case the chemotherapeutic eifect of cisplatin is also reduced.
In response to the lower SH concentrations caused by cisplatin, we observed: (a) increased activities of the serum enzymes, NADPisocitric dehydrogenase and glutathione reductase, (b) significant increases in liver isocitric dehydrogenase and kidney glucose ^phosphate dehydrogenase, all of these enzymes being associated with NADPH generation and maintenance of reduced sulphydryl groups. By constantly preventing oxidative processes, sulphydryl groups also have an important role in the maintenance of cellular membrane integrity. The lowering of the SH level caused by cisplatin could be a contributing factor to the observed decrease in mean osmotic fragility.
The effect of cisplatin was much greater on the kidney than the liver. While only one enzyme was found to change in the liver (NADP isocitric dehydrogenase, increasing by 38%), seven kidney enzymes showed a change in activity (six reduced and one increased). Renal failure in rats treated with cisplatin could be a result of the lower enzymatic activities in the kidney, s well s the less efficient oxidative phosphorylation and adenosine triphosphate production of the mitochondria. The enzyme shown to be most inhibited both in the serum and kidney is alkaline phosphatase. The reason for its great sensitivity is not clear. Through its role s a membrane enzyme involved in transmembranal transport (arnong other functions), alkaline phosphatase may be particularly involved in the renal failure and development of uraemia.
Following the administration of cisplatin, uraemia developed and the activity of serum enzymes was significantly decreased (tab. 11). This was largely reversed by supplementation with cysteine and vitamin E (but not clonidine), once again indicating on the possible potential of these compounds to reverse the toxic effects caused by cisplatin. Similar patterns, although of lesser magnitude, were also seen with other kidney enzymes (alanine aminotransferase and aspartate aminotransferase). It is, however, necessary to evaluate the efficiency of these compounds when given after cisplatin treatment rather than during treatment, since the combined supplementation of cisplatin together with vitamin E and cysteine may reduce the chemotherapeutic efficiency of cis-platin. The availability of appropriate biochemical indicators of the degree of nephrotoxicity will enable further study of these aspects of the problem, Of interest is the effect of clonidine, which did not reverse the toxic effects of cisplatin, but in most cases even increased the toxicity of the chemotherapeutic substance.
The increased blood cell volume seen in the cisplatintreated rats could be related to the renal failure, leading to loss of body fluids and haemoconcentration and therefore an increased haematocrit. The fact that total protein was reduced could be explained by the loss of protein in the urine. Significant proteinuria was seen in the cisplatin-treated rats, confirming the results of other others (9) . This is further supported by the lower serum albumin levels in the treated rats.
Evaluation of the toxicological effects of cisplatin leads to the following conclusions.
a) Blood and tissue analysis confirmed that the kidney is very sensitive to cisplatin toxicity, and more sensitive than the liver. b) An intracellular compensatory effect was observed following cisplatin administration. This compensatory process neutralized the effects 'off cisplatin, by increasing the activities of enzymes associated with NADPH production and the maintenance of sulphydryl groups in their reduced state. j c) The toxic effects and degree of renal failure were ; decreased by cysteine arid Vitamin E, which also partially neutralized the various changes in enzyine activity, etc. caused by cisplatin. j j d) Renal failures caused by the administration of cisplatin is the result of reduced activities of several en-, zymes that play a role in renal function, äs well äs reduced adenosine triphosphate production due to uncoupling of the mitochondrial oxidative phosphorylation.
